RNAZ
TransCode TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade F from latest DB weights. Momentum 7.8 / Value 58.0
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
8
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum8 · Δ7d -
Value58 · Δ7d -0.4
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
8
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
60% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
+0.3
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 7.8 / Value 58.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$8.01M
Beta
1.54
Shares Out
950.3K
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.35
Rev YoY
-
EPS YoY
-69.7%
Gross Margin
-
Op Margin
-
Net Debt
-$17.81M
Current Ratio
3.11
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology